The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global IBS Treatment Market Research Report 2024
Synopsis
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
The global IBS Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
This report aims to provide a comprehensive presentation of the global market for IBS Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IBS Treatment.
Report Scope
The IBS Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global IBS Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the IBS Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Segment by Type
IBS-D
IBS-C
IBS-M
Segment by Application
Hospitals
Clinics
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of IBS Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
The global IBS Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
This report aims to provide a comprehensive presentation of the global market for IBS Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding IBS Treatment.
Report Scope
The IBS Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global IBS Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the IBS Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Segment by Type
IBS-D
IBS-C
IBS-M
Segment by Application
Hospitals
Clinics
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of IBS Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IBS-D
1.2.3 IBS-C
1.2.4 IBS-M
1.3 Market by Application
1.3.1 Global IBS Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global IBS Treatment Market Perspective (2019-2030)
2.2 IBS Treatment Growth Trends by Region
2.2.1 Global IBS Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 IBS Treatment Historic Market Size by Region (2019-2024)
2.2.3 IBS Treatment Forecasted Market Size by Region (2025-2030)
2.3 IBS Treatment Market Dynamics
2.3.1 IBS Treatment Industry Trends
2.3.2 IBS Treatment Market Drivers
2.3.3 IBS Treatment Market Challenges
2.3.4 IBS Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top IBS Treatment Players by Revenue
3.1.1 Global Top IBS Treatment Players by Revenue (2019-2024)
3.1.2 Global IBS Treatment Revenue Market Share by Players (2019-2024)
3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by IBS Treatment Revenue
3.4 Global IBS Treatment Market Concentration Ratio
3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2023
3.5 IBS Treatment Key Players Head office and Area Served
3.6 Key Players IBS Treatment Product Solution and Service
3.7 Date of Enter into IBS Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IBS Treatment Breakdown Data by Type
4.1 Global IBS Treatment Historic Market Size by Type (2019-2024)
4.2 Global IBS Treatment Forecasted Market Size by Type (2025-2030)
5 IBS Treatment Breakdown Data by Application
5.1 Global IBS Treatment Historic Market Size by Application (2019-2024)
5.2 Global IBS Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America IBS Treatment Market Size (2019-2030)
6.2 North America IBS Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America IBS Treatment Market Size by Country (2019-2024)
6.4 North America IBS Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe IBS Treatment Market Size (2019-2030)
7.2 Europe IBS Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe IBS Treatment Market Size by Country (2019-2024)
7.4 Europe IBS Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific IBS Treatment Market Size (2019-2030)
8.2 Asia-Pacific IBS Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific IBS Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific IBS Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America IBS Treatment Market Size (2019-2030)
9.2 Latin America IBS Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America IBS Treatment Market Size by Country (2019-2024)
9.4 Latin America IBS Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa IBS Treatment Market Size (2019-2030)
10.2 Middle East & Africa IBS Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa IBS Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa IBS Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan (Ireland)
11.1.1 Allergan (Ireland) Company Detail
11.1.2 Allergan (Ireland) Business Overview
11.1.3 Allergan (Ireland) IBS Treatment Introduction
11.1.4 Allergan (Ireland) Revenue in IBS Treatment Business (2019-2024)
11.1.5 Allergan (Ireland) Recent Development
11.2 Sucampo Pharmaceuticals (U.S.)
11.2.1 Sucampo Pharmaceuticals (U.S.) Company Detail
11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
11.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
11.3 Ironwood Pharmaceuticals (U.S.)
11.3.1 Ironwood Pharmaceuticals (U.S.) Company Detail
11.3.2 Ironwood Pharmaceuticals (U.S.) Business Overview
11.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Introduction
11.3.4 Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.3.5 Ironwood Pharmaceuticals (U.S.) Recent Development
11.4 Astellas Pharma (Japan)
11.4.1 Astellas Pharma (Japan) Company Detail
11.4.2 Astellas Pharma (Japan) Business Overview
11.4.3 Astellas Pharma (Japan) IBS Treatment Introduction
11.4.4 Astellas Pharma (Japan) Revenue in IBS Treatment Business (2019-2024)
11.4.5 Astellas Pharma (Japan) Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Detail
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health IBS Treatment Introduction
11.5.4 Bausch Health Revenue in IBS Treatment Business (2019-2024)
11.5.5 Bausch Health Recent Development
11.6 Abbott Laboratories (U.S.)
11.6.1 Abbott Laboratories (U.S.) Company Detail
11.6.2 Abbott Laboratories (U.S.) Business Overview
11.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
11.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.6.5 Abbott Laboratories (U.S.) Recent Development
11.7 Synergy Pharmaceuticals (U.S.)
11.7.1 Synergy Pharmaceuticals (U.S.) Company Detail
11.7.2 Synergy Pharmaceuticals (U.S.) Business Overview
11.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Introduction
11.7.4 Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.7.5 Synergy Pharmaceuticals (U.S.) Recent Development
11.8 Ardelyx (U.S.)
11.8.1 Ardelyx (U.S.) Company Detail
11.8.2 Ardelyx (U.S.) Business Overview
11.8.3 Ardelyx (U.S.) IBS Treatment Introduction
11.8.4 Ardelyx (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.8.5 Ardelyx (U.S.) Recent Development
11.9 Nestle (Switzerland)
11.9.1 Nestle (Switzerland) Company Detail
11.9.2 Nestle (Switzerland) Business Overview
11.9.3 Nestle (Switzerland) IBS Treatment Introduction
11.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2019-2024)
11.9.5 Nestle (Switzerland) Recent Development
11.10 Sebela Pharmaceuticals (Ireland)
11.10.1 Sebela Pharmaceuticals (Ireland) Company Detail
11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
11.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2019-2024)
11.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
11.11 Probi (Sweden)
11.11.1 Probi (Sweden) Company Detail
11.11.2 Probi (Sweden) Business Overview
11.11.3 Probi (Sweden) IBS Treatment Introduction
11.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2019-2024)
11.11.5 Probi (Sweden) Recent Development
11.12 Alfasigma USA (Italy)
11.12.1 Alfasigma USA (Italy) Company Detail
11.12.2 Alfasigma USA (Italy) Business Overview
11.12.3 Alfasigma USA (Italy) IBS Treatment Introduction
11.12.4 Alfasigma USA (Italy) Revenue in IBS Treatment Business (2019-2024)
11.12.5 Alfasigma USA (Italy) Recent Development
11.13 RedHill Biopharma (Israel)
11.13.1 RedHill Biopharma (Israel) Company Detail
11.13.2 RedHill Biopharma (Israel) Business Overview
11.13.3 RedHill Biopharma (Israel) IBS Treatment Introduction
11.13.4 RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2019-2024)
11.13.5 RedHill Biopharma (Israel) Recent Development
11.14 AstraZeneca (U.K)
11.14.1 AstraZeneca (U.K) Company Detail
11.14.2 AstraZeneca (U.K) Business Overview
11.14.3 AstraZeneca (U.K) IBS Treatment Introduction
11.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2019-2024)
11.14.5 AstraZeneca (U.K) Recent Development
11.15 Ipsen (France)
11.15.1 Ipsen (France) Company Detail
11.15.2 Ipsen (France) Business Overview
11.15.3 Ipsen (France) IBS Treatment Introduction
11.15.4 Ipsen (France) Revenue in IBS Treatment Business (2019-2024)
11.15.5 Ipsen (France) Recent Development
11.16 Novartis (Switzerland)
11.16.1 Novartis (Switzerland) Company Detail
11.16.2 Novartis (Switzerland) Business Overview
11.16.3 Novartis (Switzerland) IBS Treatment Introduction
11.16.4 Novartis (Switzerland) Revenue in IBS Treatment Business (2019-2024)
11.16.5 Novartis (Switzerland) Recent Development
11.17 Takeda Pharmaceutical Company (Japan)
11.17.1 Takeda Pharmaceutical Company (Japan) Company Detail
11.17.2 Takeda Pharmaceutical Company (Japan) Business Overview
11.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Introduction
11.17.4 Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2019-2024)
11.17.5 Takeda Pharmaceutical Company (Japan) Recent Development
11.18 Synthetic Biologics (U.S.)
11.18.1 Synthetic Biologics (U.S.) Company Detail
11.18.2 Synthetic Biologics (U.S.) Business Overview
11.18.3 Synthetic Biologics (U.S.) IBS Treatment Introduction
11.18.4 Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.18.5 Synthetic Biologics (U.S.) Recent Development
11.19 Protagonist Therapeutics (U.S.)
11.19.1 Protagonist Therapeutics (U.S.) Company Detail
11.19.2 Protagonist Therapeutics (U.S.) Business Overview
11.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Introduction
11.19.4 Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.19.5 Protagonist Therapeutics (U.S.) Recent Development
11.20 Pfizer (U.S.)
11.20.1 Pfizer (U.S.) Company Detail
11.20.2 Pfizer (U.S.) Business Overview
11.20.3 Pfizer (U.S.) IBS Treatment Introduction
11.20.4 Pfizer (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.20.5 Pfizer (U.S.) Recent Development
11.21 Lexicon Pharmaceuticals (U.S.)
11.21.1 Lexicon Pharmaceuticals (U.S.) Company Detail
11.21.2 Lexicon Pharmaceuticals (U.S.) Business Overview
11.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Introduction
11.21.4 Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.21.5 Lexicon Pharmaceuticals (U.S.) Recent Development
11.22 Innovate Biopharmaceuticals (U.S.)
11.22.1 Innovate Biopharmaceuticals (U.S.) Company Detail
11.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
11.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
11.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2019-2024)
11.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
